Clin Lab Med
. 2025 Mar;45(1):111-136.
doi: 10.1016/j.cll.2024.10.007. Epub 2024 Dec 20. A Meta-analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Anti-spike Immunoglobulin G Antibody Durability up to 9 Months After Full Vaccination in Adults
Maura C Dodge 1 , Christina Ellervik 2 , Yachana Kataria 3
Affiliations
This meta-analysis aims to estimate temporal decline in vaccine-induced antibodies against severe acute respiratory syndrome coronavirus 2 up to 9 months after full vaccination contributing to overall understanding of coronavirus disease 2019 infection protection. We identified 15 eligible studies and calculated standardized mean differences (SMD) between antibody concentrations at 1, 3, 6, and 9 months after full vaccination. Overall SMD between 1 month after vaccination and 3 months was -1.14 (95% CI -1.52, -0.76), at 6 months was -1.06 (95% CI -1.30, -0.81), and at 9 months, it was -0.77 (95% CI -0.94, -0.60) suggesting a moderate decline over time.
Keywords: Antibodies; Antibody durability; SARS-CoV-2; mRNA vaccine.
. 2025 Mar;45(1):111-136.
doi: 10.1016/j.cll.2024.10.007. Epub 2024 Dec 20. A Meta-analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Anti-spike Immunoglobulin G Antibody Durability up to 9 Months After Full Vaccination in Adults
Maura C Dodge 1 , Christina Ellervik 2 , Yachana Kataria 3
Affiliations
- PMID: 39892931
- DOI: 10.1016/j.cll.2024.10.007
This meta-analysis aims to estimate temporal decline in vaccine-induced antibodies against severe acute respiratory syndrome coronavirus 2 up to 9 months after full vaccination contributing to overall understanding of coronavirus disease 2019 infection protection. We identified 15 eligible studies and calculated standardized mean differences (SMD) between antibody concentrations at 1, 3, 6, and 9 months after full vaccination. Overall SMD between 1 month after vaccination and 3 months was -1.14 (95% CI -1.52, -0.76), at 6 months was -1.06 (95% CI -1.30, -0.81), and at 9 months, it was -0.77 (95% CI -0.94, -0.60) suggesting a moderate decline over time.
Keywords: Antibodies; Antibody durability; SARS-CoV-2; mRNA vaccine.